StockData
INSMED Inc logo

INSMED Inc (INSM) company profile

INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3099% above fair value
$121.86−1.02 (-0.83%)

Close on Nov 17, 2026Market cap $26.73BP/E –Yield –

About Insmed

Pharmaceutical Preparations, SIC 2834

This biopharmaceutical company focuses on discovering, developing, and commercializing novel therapies for serious respiratory, immunological, inflammatory, and rare diseases. Its commercial portfolio features two approved products: ARIKAYCE, an inhaled liposomal antibacterial treatment for refractory Mycobacterium avium complex lung infections, and BRINSUPRI, an oral daily tablet indicated for non-cystic fibrosis bronchiectasis. The company also advances a clinical pipeline that includes TPIP, an inhaled dry-powder prodrug formulation targeting pulmonary arterial hypertension and related interstitial lung disorders, alongside gene therapy candidates for rare conditions such as Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its primary end customers are adult and adolescent patients experiencing severe, chronic, and debilitating diseases with limited existing treatment alternatives.

The enterprise maintains an international operating scale, securing regulatory clearances and distributing treatments across North America, Europe, and Asia. Its therapies have achieved commercial approvals and distribution across the United States, Japan, the United Kingdom, and European Union member nations including France, Germany, Italy, Spain, Belgium, the Netherlands, and Ireland. The company's global clinical development programs encompass operations spanning hundreds of trial sites across dozens of countries. The excerpt does not disclose the location of the corporate headquarters.

Summary of the business section of Insmed's latest annual report, written by StockData.

Company profile

Company

Legal name
INSMED Inc
Headquarters
Bridgewater, NJ
Address
700 Us Highway 202/206 08807
Phone
(908) 977-9900
Website
insmed.com
Employees
1,664, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Virginia
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Iselin, New Jersey

Stock & identifiers

Ticker
INSM
Exchange
Nasdaq
IPO date
Jun 1, 2000
Shares outstanding
219M, Oct 23, 2026
Public float
$21.10B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-10 reverse, Mar 3, 2011; 1-for-4 reverse, Jul 31, 2000
SEC CIK
1104506
CUSIP
457669307
ISIN
US4576693075
FIGI
BBG000BWM5P3
Share class FIGI
BBG001S9SKW7
LEI
529900Q55QAG41CCAC11
EIN
54-1972729

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
William LewisChair and CEO, Director492,982
Patrick Kevin KaneCorporate Controller9,921
Roger AdsettChief Operating Officer338,594
Martina M.D. FlammerChief Medical Officer60,486
Michael Alexander SmithChief Legal Officer37,648
Samuele ButeraSVP, GM, Global Respiratory7,342
Sara BonsteinChief Financial Officer69,082
Orlov S. Nicole SchaefferChief People Strategy Officer63,911
John Drayton WiseChief Commercial Officer133,015
Paul HudsonDirector6,139
Utpal KoppikarDirector6,139
David R. BrennanDirector99,238
Melvin Sharoky MdDirector267,901
Leo LeeDirector57,971
Elizabeth M. AndersonDirector62,034
Clarissa DesjardinsDirector73,337
Carol SchaferDirector66,622
David W. J. McGirrDirector97,723

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$14.47M$127.86M$4.54M$523$120
FY2024$10.94M$51.86M$4.12M$207$91
FY2023$10.41M$17.72M$4.17M$93$92
FY2022$7.79M$4.33M$3.96M$60$89
FY2021$7.32M$2.81M$3.32M$82$99
FY2020$6.19M$12.66M$2.84M$139$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
William H. Lewis
CEO
$854.55K$3.00M$9.00M$1.50M$117.41K$14.47M+32%
Sara Bonstein
Chief Financial Officer
$583.19K$874.97K$2.62M$510.29K$24.19K$4.62M+15%
Roger Adsett
Chief Operating Officer
$622.59K$874.97K$2.62M$544.77K$24.30K$4.69M+10%
Martina Flammer, M.D.
Chief Medical Officer
$634.19K$874.97K$2.62M$554.92K$27.66K$4.72M+15%
Michael A. Smith
Chief Legal Officer
$595.27K$749.95K$2.25M$520.86K$21.96K$4.14M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of 1,664 full-time employees: 736 in research, clinical, regulatory, medical affairs and quality assurance; 107 in technical operations, manufacturing and quality control; 266 in general and administrative functions; and 555 in commercial activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?